Pneumagen

St Andrews-based biotech firm Pneumagen has secured £8 million in financing from existing and new investors to support the continued Phase 2 development of Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs). Pneu

A round-up of business news from across Scotland featuring: Alpha Solway's visor production for the NHS, Edinburgh Gin's new Gin Fizz, Smarter Grid Solutions' £20 million R&D milestone, Sunamp's £50,00 grant from Innovate UK, Pneumagen's £4m invest